Adrenal insufficiency

Česká verzia

Authors: Filip Gabalec; Jan Čáp
Authors place of work: IV. interní hematologická klinika LF UK a FN Hradec Králové, přednosta doc. MUDr. Pavel Žák, Ph. D.
Published in the journal: Vnitř Lék 2015; 61(10): 858-861
Category: Reviews

Summary

Adrenal insufficiency is a potentially life threatening condition. The paper deals with differential diagnostics and limits of dynamic testing, possibilities of de-escalation of corticosteroid therapy and substitution therapy with glucocorticoids, mineralocorticoids and androgens. New replacement possibilities are mentioned including those in development.

Key words:
Addison‘s disease – adrenal insufficiency – hypopituitarism

Zdroje

1. Sterzl I, Hrda P. Immunoendocrine associations in adrenal glands. Vnitř Lék 2010; 56(12): 1286–1291.

2. Bancos I, Hahner S, Tomlinson J et al. Diagnosis and management of adrenal insufficiency. Lancet Diabetes Endocrinol 2015; 3(3): 216–226.

3. Kršek M. Pacient s adrenokortikální insuficiencí v ordinaci internisty. Interní Med 2011; 13(4): 163–166.

4. Maghnie M, Uga E, Temporini F et al. Evaluation of adrenal function in patients with growth hormone deficiency and hypothalamic-pituitary disorders: comparison between insulin-induced hypoglycemia, low-dose ACTH, standard ACTH and CRH stimulation tests. Eur J Endocrinol 2005; 152(5): 735–741.

5. Qureshi AC, Bahri A, Breen LA et al. The influence of the route of oestrogen administration on serum levels of cortisol-binding globulin and total cortisol. Clin Endocrinol (Oxf) 2007; 66(5): 632–635.

6. Oelkers W, Diederich S, Bahr V. Diagnosis and therapy surveillance in Addison‘s disease: rapid adrenocorticotropin (ACTH) test and measurement of plasma ACTH, renin activity, and aldosterone. J Clin Endocrinol Metab 1992; 75(1): 259–264.

7. Esteban NV, Yergey AL Cortisol production rates measured by liquid chromatography/mass spectrometry. Steroids 1990; 55(4): 152–158.

8. Weitzman ED, Fukushima D, Nogeire C et al. Twenty-four hour pattern of the episodic secretion of cortisol in normal subjects. J Clin Endocrinol Metab 1971; 33(1): 14–22.

9. Charmandari E, Nicolaides NC, Chrousos GP. Adrenal insufficiency. Lancet 2014; 383(9935): 2152–2167.

10. Danilowicz K, Bruno OD, Manavela M et al. Correction of cortisol overreplacement ameliorates morbidities in patients with hypopituitarism: a pilot study. Pituitary 2008; 11(3): 279–285.

11. Hahner S, Allolio B. Therapeutic management of adrenal insufficiency. Best Pract Res Clin Endocrinol Metab 2009; 23(2): 167–179.

12. Quinkler M, Hahner S. What is the best long-term management strategy for patients with primary adrenal insufficiency? Clin Endocrinol (Oxf) 2012; 76(1): 21–25.

13. Barbetta L, Dall‘Asta C, Re T et al. Comparison of different regimens of glucocorticoid replacement therapy in patients with hypoadrenalism. J Endocrinol Invest 2005; 28(7): 632–637.

14. Johannsson G, Bergthorsdottir R, Nilsson AG et al. Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study. Eur J Endocrinol 2009; 161(1): 119–130.

15. Johannsson G, Nilsson AG, Bergthorsdottir R et al. Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation. J Clin Endocrinol Metab 2012; 97(2): 473–481.

16. Mallappa A, Sinaii N, Kumar P et al. A phase 2 study of Chronocort, a modified-release formulation of hydrocortisone, in the treatment of adults with classic congenital adrenal hyperplasia. J Clin Endocrinol Metab 2015; 100(3): 1137–1145.

17. Whitaker MJ, Debono M, Huatan H et al. An oral multiparticulate, modified-release, hydrocortisone replacement therapy that provides physiological cortisol exposure. Clin Endocrinol (Oxf) 2014; 80(4): 554–561.

18. Boonen E, Vervenne H, Meersseman P et al. Reduced cortisol metabolism during critical illness. N Engl J Med 2013; 368(16): 1477–1488.

19. Arlt W, Callies F, Allolio B. DHEA replacement in women with adrenal insufficiency – pharmacokinetics, bioconversion and clinical effects on well-being, sexuality and cognition. Endocr Res 2000; 26(4): 505–511.

20. Bilger M, Speraw S, LaFranchi SH et al. Androgen replacement in adolescents and young women with hypopituitarism. J Pediatr Endocrinol Metab 2005; 18(4): 355–362.

21. Binder G, Weber S, Ehrismann M et al. Effects of dehydroepiandrosterone therapy on pubic hair growth and psychological well-being in adolescent girls and young women with central adrenal insufficiency: a double-blind, randomized, placebo-controlled phase III trial. J Clin Endocrinol Metab 2009; 94(4): 1182–1190.

22. Wierman ME, Arlt W, Basson R et al. Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2014; 99(10): 3489–3510.

23. Vouillarmet J, Buron F, Houzard C et al. The first simultaneous kidney-adrenal gland-pancreas transplantation: outcome at 1 year. Am J Transplant 2013; 13(7): 1905–1909.

24. Ludwig B, Reichel A, Steffen A et al. Transplantation of human islets without immunosuppression. Proc Natl Acad Sci USA 2013; 110(47): 19054–19058.

25. Cox DB, Platt RJ, Zhang F. Therapeutic genome editing: prospects and challenges. Nat Med 2015; 21(2): 121–131.

26. Ruiz-Babot G, Hadjidemetriou I, King PJ et al. New directions for the treatment of adrenal insufficiency. Front Endocrinol (Lausanne) 2015; 6: 70. Dostupné z DOI: <http://dx.doi.org/10.3389/fendo.2015.00070>.

27. Pearce SH, Mitchell AL, Bennett S et al. Adrenal steroidogenesis after B lymphocyte depletion therapy in new-onset Addison‘s disease. J Clin Endocrinol Metab 2012; 97(10): E1927-E1932.

28. Gan EH, MacArthur K, Mitchell AL et al. Residual adrenal function in autoimmune Addison‘s disease: improvement after tetracosactide (ACTH1–24) treatment. J Clin Endocrinol Metab 2014; 99(1): 111–118.

29. Bergthorsdottir R, Leonsson-Zachrisson M, Oden A et al. Premature mortality in patients with Addison‘s disease: a population-based study. J Clin Endocrinol Metab 2006; 91(12): 4849–4853.